Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 1;21(9):105.
doi: 10.1007/s11886-019-1178-9.

Engineering Functional Cardiac Tissues for Regenerative Medicine Applications

Affiliations

Engineering Functional Cardiac Tissues for Regenerative Medicine Applications

Martin L Tomov et al. Curr Cardiol Rep. .

Abstract

Purpose of review: Tissue engineering has expanded into a highly versatile manufacturing landscape that holds great promise for advancing cardiovascular regenerative medicine. In this review, we provide a summary of the current state-of-the-art bioengineering technologies used to create functional cardiac tissues for a variety of applications in vitro and in vivo.

Recent findings: Studies over the past few years have made a strong case that tissue engineering is one of the major driving forces behind the accelerating fields of patient-specific regenerative medicine, precision medicine, compound screening, and disease modeling. To date, a variety of approaches have been used to bioengineer functional cardiac constructs, including biomaterial-based, cell-based, and hybrid (using cells and biomaterials) approaches. While some major progress has been made using cellular approaches, with multiple ongoing clinical trials, cell-free cardiac tissue engineering approaches have also accomplished multiple breakthroughs, although drawbacks remain. This review summarizes the most promising methods that have been employed to generate cardiovascular tissue constructs for basic science or clinical applications. Further, we outline the strengths and challenges that are inherent to this field as a whole and for each highlighted technology.

Keywords: 3D modeling; Bioprinting; Cardiac tissue engineering; Cardiovascular regenerative medicine; Patient-specific precision medicine; Vascular network.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical Standards

Conflict of Interest Martin L. Tomov, Carmen J. Gil, Alexander Cetnar, Andrea S. Theus, Bryanna J. Lima, Joy E. Nish, Holly D. Bauser-Heaton, and Vahid Serpooshan declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Schematic summary of cardiovascular tissue engineering paradigms (inner circle) and commonly used bioengineering approaches (outer circle), including 3D printing and bioprinting, cell self-assembly approaches, cell/hydrogel/gene injection therapies, 3D cast tissue constructs (reconstructed from [41]), decellularized tissue scaffolds (reconstructed from [42, 43]), micropatterning and stamping (reconstructed from [44]), electrospinning, and organ-on-a-chip methods

References

    1. Serpooshan V, Zhao M, Metzler SA, Wei K, Shah PB, Wang A, et al. Use of bio-mimetic three-dimensional technology in therapeutics for heart disease. Bioengineered. 2014;5(3):193–7. - PMC - PubMed
    1. Doppler SA, Deutsch MA, Serpooshan V, Li G, Dzilic E, Lange R, et al. Mammalian heart regeneration: the race to the finish line. Circ Res. 2017;120(4):630–2. - PMC - PubMed
    1. Duan B State-of-the-art review of 3D bioprinting for cardiovascular tissue engineering. Ann Biomed Eng. 2017;45(1):195–209. - PubMed
    1. Ahadian S, Khademhosseini A. Smart scaffolds in tissue regeneration. Regen Biomater. 2018;5(3):125–8. - PMC - PubMed
    1. Ashammakhi N, et al. Advances and future perspectives in 4D bioprinting. Biotechnol J. 2018;13(12):e1800148. - PMC - PubMed

Publication types

MeSH terms

Substances